Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) as a metabolomics platform in cervical cancer screening

Background: The introduction of high-risk human papillomavirus (hrHPV) testing as part of primary cervical screening is anticipated to improve sensitivity, but also the number of women who will screen positive. Reflex cytology is the preferred triage test in most settings but has limitations includi...

Full description

Bibliographic Details
Main Authors: Maria Paraskevaidi, Simon J.S. Cameron, Eilbhe Whelan, Sarah Bowden, Menelaos Tzafetas, Anita Mitra, Anita Semertzidou, Antonis Athanasiou, Phillip R. Bennett, David A. MacIntyre, Zoltan Takats, Maria Kyrgiou
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:EBioMedicine
Subjects:
CIN
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396420303935
id doaj-9c8e64b9a0f649ea978822fe912f3328
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Maria Paraskevaidi
Simon J.S. Cameron
Eilbhe Whelan
Sarah Bowden
Menelaos Tzafetas
Anita Mitra
Anita Semertzidou
Antonis Athanasiou
Phillip R. Bennett
David A. MacIntyre
Zoltan Takats
Maria Kyrgiou
spellingShingle Maria Paraskevaidi
Simon J.S. Cameron
Eilbhe Whelan
Sarah Bowden
Menelaos Tzafetas
Anita Mitra
Anita Semertzidou
Antonis Athanasiou
Phillip R. Bennett
David A. MacIntyre
Zoltan Takats
Maria Kyrgiou
Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) as a metabolomics platform in cervical cancer screening
EBioMedicine
Cervical cancer
CIN
Cervical cancer screening
Liquid-based cytology
HPV tests
Metabolomics
author_facet Maria Paraskevaidi
Simon J.S. Cameron
Eilbhe Whelan
Sarah Bowden
Menelaos Tzafetas
Anita Mitra
Anita Semertzidou
Antonis Athanasiou
Phillip R. Bennett
David A. MacIntyre
Zoltan Takats
Maria Kyrgiou
author_sort Maria Paraskevaidi
title Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) as a metabolomics platform in cervical cancer screening
title_short Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) as a metabolomics platform in cervical cancer screening
title_full Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) as a metabolomics platform in cervical cancer screening
title_fullStr Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) as a metabolomics platform in cervical cancer screening
title_full_unstemmed Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) as a metabolomics platform in cervical cancer screening
title_sort laser-assisted rapid evaporative ionisation mass spectrometry (la-reims) as a metabolomics platform in cervical cancer screening
publisher Elsevier
series EBioMedicine
issn 2352-3964
publishDate 2020-10-01
description Background: The introduction of high-risk human papillomavirus (hrHPV) testing as part of primary cervical screening is anticipated to improve sensitivity, but also the number of women who will screen positive. Reflex cytology is the preferred triage test in most settings but has limitations including moderate diagnostic accuracy, lack of automation, inter-observer variability and the need for clinician-collected sample. Novel, objective and cost-effective approaches are needed. Methods: In this study, we assessed the potential use of an automated metabolomic robotic platform, employing the principle of laser-assisted Rapid Evaporative Ionisation Mass Spectrometry (LA-REIMS) in cervical cancer screening. Findings: In a population of 130 women, LA-REIMS achieved 94% sensitivity and 83% specificity (AUC: 91.6%) in distinguishing women testing positive (n = 65) or negative (n = 65) for hrHPV. We performed further analysis according to disease severity with LA-REIMS achieving sensitivity and specificity of 91% and 73% respectively (AUC: 86.7%) in discriminating normal from high-grade pre-invasive disease. Interpretation: This automated high-throughput technology holds promise as a low-cost and rapid test for cervical cancer screening and triage. The use of platforms like LA-REIMS has the potential to further improve the accuracy and efficiency of the current national screening programme. Funding: Work was funded by the MRC Imperial Confidence in Concept Scheme, Imperial College Healthcare Charity, British Society for Colposcopy and Cervical Pathology, National Research Development and Innovation Office of Hungary, Waters corporation and NIHR BRC.
topic Cervical cancer
CIN
Cervical cancer screening
Liquid-based cytology
HPV tests
Metabolomics
url http://www.sciencedirect.com/science/article/pii/S2352396420303935
work_keys_str_mv AT mariaparaskevaidi laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
AT simonjscameron laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
AT eilbhewhelan laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
AT sarahbowden laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
AT menelaostzafetas laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
AT anitamitra laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
AT anitasemertzidou laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
AT antonisathanasiou laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
AT philliprbennett laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
AT davidamacintyre laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
AT zoltantakats laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
AT mariakyrgiou laserassistedrapidevaporativeionisationmassspectrometrylareimsasametabolomicsplatformincervicalcancerscreening
_version_ 1724453602119909376
spelling doaj-9c8e64b9a0f649ea978822fe912f33282020-11-25T03:59:40ZengElsevierEBioMedicine2352-39642020-10-0160103017Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) as a metabolomics platform in cervical cancer screeningMaria Paraskevaidi0Simon J.S. Cameron1Eilbhe Whelan2Sarah Bowden3Menelaos Tzafetas4Anita Mitra5Anita Semertzidou6Antonis Athanasiou7Phillip R. Bennett8David A. MacIntyre9Zoltan Takats10Maria Kyrgiou11Department of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United Kingdom; Department of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, United KingdomDepartment of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United Kingdom; Institute for Global Food Security, School of Biological Sciences, Queen's University, Belfast, Northern Ireland BT5 9DL, United KingdomDepartment of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United Kingdom; Imperial College Healthcare NHS Trust, London, United KingdomDepartment of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United Kingdom; Imperial College Healthcare NHS Trust, London, United KingdomDepartment of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United KingdomDepartment of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United KingdomDepartment of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United Kingdom; Imperial College Healthcare NHS Trust, London, United KingdomDepartment of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United Kingdom; Imperial College Healthcare NHS Trust, London, United KingdomDepartment of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United Kingdom; Imperial College Healthcare NHS Trust, London, United Kingdom; March of Dimes European Preterm Birth Research Centre, Imperial College London, London W12 0NN, United KingdomDepartment of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United Kingdom; March of Dimes European Preterm Birth Research Centre, Imperial College London, London W12 0NN, United KingdomDepartment of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United Kingdom; Corresponding authors.Department of Metabolism, Digestion and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 665 Sir Alexander Fleming Building, South Kensington Campus, London W12 0NN, United Kingdom; Imperial College Healthcare NHS Trust, London, United Kingdom; Corresponding authors.Background: The introduction of high-risk human papillomavirus (hrHPV) testing as part of primary cervical screening is anticipated to improve sensitivity, but also the number of women who will screen positive. Reflex cytology is the preferred triage test in most settings but has limitations including moderate diagnostic accuracy, lack of automation, inter-observer variability and the need for clinician-collected sample. Novel, objective and cost-effective approaches are needed. Methods: In this study, we assessed the potential use of an automated metabolomic robotic platform, employing the principle of laser-assisted Rapid Evaporative Ionisation Mass Spectrometry (LA-REIMS) in cervical cancer screening. Findings: In a population of 130 women, LA-REIMS achieved 94% sensitivity and 83% specificity (AUC: 91.6%) in distinguishing women testing positive (n = 65) or negative (n = 65) for hrHPV. We performed further analysis according to disease severity with LA-REIMS achieving sensitivity and specificity of 91% and 73% respectively (AUC: 86.7%) in discriminating normal from high-grade pre-invasive disease. Interpretation: This automated high-throughput technology holds promise as a low-cost and rapid test for cervical cancer screening and triage. The use of platforms like LA-REIMS has the potential to further improve the accuracy and efficiency of the current national screening programme. Funding: Work was funded by the MRC Imperial Confidence in Concept Scheme, Imperial College Healthcare Charity, British Society for Colposcopy and Cervical Pathology, National Research Development and Innovation Office of Hungary, Waters corporation and NIHR BRC.http://www.sciencedirect.com/science/article/pii/S2352396420303935Cervical cancerCINCervical cancer screeningLiquid-based cytologyHPV testsMetabolomics